FDA Streamlines Manufacturing Rules to Accelerate Gene Therapy Innovation

White Oak, Monday, 12 January 2026.
The FDA’s strategic pivot to broad regulatory flexibility for cell and gene therapies signals a critical reduction in development bottlenecks, directly addressing the sector’s explosive growth and expediting market access for high-value biopharmaceuticals.